natgillin/translations-raw huggingface dataset:
Axura 15 mg film-coated tablets are presented as orange to grey-orange, oval-oblong with imprint ‘15’ on one side and imprint ‘MEM’ on the other side.
Axura 15 mg filmsko obložene tablete so oranžne do sivo oranžne, ovalne in podolgovate z vtisnjeno številko "15" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Axura 15 mg film-coated tablets.
Axura 15 mg filmsko obložene tablete.
Axura 20 mg film-coated tablets are presented as are pale red to grey-red, oval-oblong with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Axura 20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalne in podolgovate z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Axura 20 mg film-coated tablets.
Axura 20 mg filmsko obložene tablete
Axura 5 mg film-coated tablets are presented as white to off-white, oval-oblong with imprint ‘5’ on one side and imprint ‘MEM’ on the other side.
Axura 5 mg filmsko obložene tablete so bele do belkaste, ovalne in podolgovate z vtisnjeno številko "5" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Axura 5 mg film-coated tablets.
Axura 5 mg filmsko obložene tablete.
Axura 5 mg/pump actuation, oral solution
Axura 5 mg/pritisk peroralna raztopina.
Axura 5 mg/pump actuation, oral solution memantine hydrochloride
Axura 5 mg/pritisk peroralna raztopina. memantinijev klorid.
Axura 5mg, 10mg, 15mg, 20 mg film-coated tablets Memantine hydrochloride
Axura 5 mg, 10 mg, 15 mg, 20 mg filmsko obložene tablete memantinijev klorid
Axura 5mg/pump actuation, oral solution.
Axura 5 mg/pritisk peroralna raztopina
Axura belongs to a group of medicines called NMDA- receptor antagonists.
Axura spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.
Axura film-coated tablets are presented as pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Axura filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno podolgovate, filmsko obložene tablete z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Axura film-coated tablets are presented as pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side
Axura filmsko obložene tablete so bledo rumene do rumene, ovalne, filmsko obložene tablete z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in besedo "M M" na drugi strani.
Axura has been studied in three main studies including a total of 1,125 patients with Alzheimer’s disease, some of whom had taken other medicines for their disease in the past.
Zdravilo Axura so proučevali v treh glavnih študijah, ki so vključevale skupno 1 125 bolnikov z Alzheimerjevo boleznijo, pri čemer so nekateri izmed njih v preteklosti prejemali druga zdravila za zdravljenje te bolezni.
Axura is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Zdravilo Axura uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Axura is used to treat patients with moderate to severe Alzheimer’s disease.
Zdravilo Axura se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Axura memantine hydrochloride
Axura memantinijev klorid
Axura oral solution is available in bottles of 50 ml, 100 ml or a multipack of 500ml (10 x 50 ml).
Axura peroralna raztopina je na voljo v stekleničkah po 50 ml, 100 ml ali v večkratnem pakiranju po 500 ml (10 x 50 ml).
Axura should be administered once a day and should be taken at the same time every day.
Zdravilo Axura je treba dajati enkrat dnevno in ob istem času vsak dan.
Axura was more effective than placebo at controlling the symptoms of Alzheimer’s disease.
Zdravilo Axura je bilo pri nadzorovanju simptomov Alzheimerjeve bolezni učinkovitejše od placeba.
Axura with food and drink
Jemanje zdravila Axura skupaj s hrano in pijačo
Azacitidine has minor or moderate influence on the ability to drive and use machines.
Azacitidin ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Azagly-nafarelin 1600 g/ml as azagly-nafarelin acetate.
Azagli-nafarelin, 1600 µg/ml, v obliki azagli-nafarelin acetata
Azagly-nafarelin 1600 g/ml as azagly-nafarelin acetate.
Azagli-nafarelin, 1600 µg/ml, v obliki azagli-nafarelin-acetata
AZARGA 10 mg/mL + 5 mg/mL eye drops, suspension
AZARGA 10 mg/ml + 5 mg/ml kapljice za oko, suspenzija
AZARGA 10 mg/ml + 5 mg/ml eye drops, suspension Brinzolamide/Timolol
AZARGA 10 mg/ml + 5 mg/ml kapljice za oko, suspenzija brinzolamid/timolol
AZARGA has minor influence on the ability to drive and use machines.
Zdravilo AZARGA ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Azarga is given as one drop into the affected eye(s) twice a day.
Odmerek zdravila Azarga je ena kapljica v prizadeto oko (očesi) dvakrat na dan.
AZARGA is not recommended for children and adolescents under 18 years.
Zdravilo AZARGA ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
AZARGA may be used while wearing contact lenses with careful monitoring (see below under ‘Benzalkonium chloride’).
Zdravilo AZARGA lahko uporabljajo nosilci kontaktnih leč s skrbnim spremljanjem (glejte spodaj pod 'Benzalkonijev klorid').
azathioprine or other medicines which suppress your immune system (given after a transplant operation)
azatioprin ali druga zdravila, ki zavirajo imunski sistem (uporabljajo se po presaditveni operaciji),
azathioprine or other medicines which suppress your immune system - given after a transplant operation
azatioprin ali druga zdravila, ki zavirajo imunski sistem – uporabljajo se po presaditveni operaciji,
azathioprine or other medicines which suppress your immune system – given after a transplant operation
azatioprin ali druga zdravila, ki zavirajo imunski sistem – uporabljajo se po presaditveni operaciji,
azetazolamide (to treat increased pressure in the eye also called glaucoma)
acetazolamid (za zdravljenje povišanega tlaka v očesu, ki se imenuje tudi glavkom)
Azilect can be used either alone, or as an add-on to levodopa (another medicine used in Parkinson’s disease) in patients who are having ‘fluctuations’ towards the end of the period between levodopa doses.
Zdravilo Azilect se lahko uporablja samostojno ali kot dodatek levodopi (drugemu zdravilu, ki se uporablja pri Parkinsonovi bolezni) pri bolnikih z nihanji proti koncu obdobja med dvema odmerkoma levodope.
Azilect has been studied in three main studies involving a total of 1,563 patients with Parkinson’s disease.
Zdravilo Azilect so raziskovali v treh glavnih študijah, ki so vključevale skupaj 1 563 bolnikov s Parkinsonovo boleznijo.
AZILECT helps to increase and sustain levels of dopamine in the brain.
Zdravilo AZILECT pomaga zvišati in vzdrževati raven dopamina v možganih.
AZILECT is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Zdravilo AZILECT je indicirano za zdravljenje idiopatske Parkinsonove bolezni (PB) kot monoterapija (brez levodope) ali kot dodatna terapija (z levodopo) pri bolnikih z nihanji končnih odmerkov.
AZILECT is not recommended for use under the age of 18.
Jemanje zdravila AZILECT ni priporočeno za mlajše od 18 let.
AZILECT is used for the treatment of Parkinson’s disease.
Zdravilo AZILECT se uporablja pri zdravljenju Parkinsonove bolezni.
Azilect is used to treat Parkinson’s disease.
Zdravilo Azilect se uporablja za zdravljenje bolnikov s Parkinsonovo boleznijo.
AZILECT may be taken with or without food.
Zdravilo AZILECT lahko jemljete bodisi s hrano bodisi brez nje.
AZILECT may be taken with or without food.
Zdravilo AZILECT lahko vzamete s hrano ali brez nje.
Azilect must not be used with other monoamine oxidase inhibitors including medicines and herbal preparations obtained without prescription such as St John’s wort.
Zdravilo Azilect se ne sme uporabljati skupaj z drugimi zaviralci monoaminooksidaz, vključno z zdravili ali rastlinskimi pripravki, ki se dobijo brez recepta, kot je šentjanževka.
AZILECT tablets are presented as white to off-white, round, flat, bevelled tablets, debossed with “GIL” and “1” underneath on one side and plain on the other side.
Zdravilo AZILECT tablete so bele do belkaste, okrogle, ploščate, prirezane tablete z vtisnjenim "GIL" in "1" spodaj na eni strani in brez odtisov na drugi strani.
Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues (see section 5.2).
Medoksomilazilsartanat je peroralno aktivno predzdravilo, ki se hitro spremeni v aktivni del – azilsartan, ki selektivno nasprotuje učinkom angiotenzina II tako, da preprečuje, da bi se le-ta vezal na AT1 receptorje v več tkivih (glejte poglavje 5.2).
Azithromycin or Ciprofloxacin
Azitromicin ali ciprofloksacin
Azithromycin/efavirenz (600 mg single dose/400 mg once daily)
azitromicin/efavirenz (enkratni odmerek 600 mg/ 400 mg enkrat na dan)
Azithromycin/Efavirenz (600 mg single dose/400 mg once daily)
azitromicin/efavirenz (enkratni odmerek 600 mg/400 mg enkrat na dan)
Azole anti-fungal agents
Azolni antimikotiki
AZOLE ANTIFUNGAL AGENTS
AZOLNI ANTIMIKOTIKI
Azomyr 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30,
5 mg filmsko obložene tablete Azomyr so na voljo v pretisnih omotih po 1, 2, 3, 5, 7, 10, 14, 15, 20,
Azomyr 5 mg film-coated tablets desloratadine
Azomyr 5 mg filmsko obložena tableta desloratadin
Azomyr contains desloratadine which is an antihistamine.
Zdravilo Azomyr vsebuje desloratadin, ki je antihistaminik.
Azomyr is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Zdravilo Azomyr se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
Azomyr is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Zdravilo Azomyr je indicirano pri odraslih in mladostnikih, starih 12 let in več, za lajšanje simptomov:
Azomyr is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:
Zdravilo Azomyr je indicirano pri odraslih, mladostnikih, starih 12 let in več, in otrocih, starih 6 – 11 let, za lajšanje simptomov:
Azomyr is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:
Zdravilo Azomyr je indicirano pri odraslih, mladostnikih in otrocih, starejših od 1 leta, za lajšanje simptomov:
Azomyr may be taken with or without a meal.
Zdravilo Azomyr se lahko jemlje s hrano ali brez nje.
Azomyr oral solution contains sorbitol
Zdravilo Azomyr peroralna raztopina vsebuje sorbitol
Azomyr oral solution contains sorbitol.
Azomyr peroralna raztopina vsebuje sorbitol.
Azomyr oral solution is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Zdravilo Azomyr peroralna raztopina se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
Azomyr oral solution is an antiallergy medicine that does not make you drowsy.
Zdravilo Azomyr peroralna raztopina je zdravilo proti alergiji, ki ne povzroča zaspanosti.
Azomyr oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap.
Azomyr peroralna raztopina je na voljo v stekleničkah po 30, 50, 60, 100, 120, 150, 225 in 300 ml, z zaporko, varno za otroke.
Azomyr oral solution with food, drink and alcohol
Zdravilo Azomyr peroralna raztopina skupaj s hrano, pijačo in alkoholom
Azomyr orodispersible tablet contains aspartame
Zdravilo Azomyr orodisperzibilna tableta vsebuje aspartam
Azomyr orodispersible tablet does not need to be taken with water or liquid.
Zdravila Azomyr orodisperzibilna tableta vam ni treba jemati z vodo ali tekočino.
Azomyr orodispersible tablet is packed in unit dose blisters in packs of
Azomyr orodisperzibilne tablete so na voljo v pretisnih omotih po
Azomyr orodispersible tablet with food, drink and alcohol
Zdravilo Azomyr orodisperzibilna tableta skupaj s hrano, pijačo in alkoholom
Azomyr tablets effectively controlled symptoms for 24 hours.
Zdravilo Azomyr učinkovito obvladuje te simptome za čas 24 ur.
Azomyr tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
Zdravilo Azomyr je učinkovito ublažilo težave, povezane s sezonskim alergijskim rinitisom, kar je pokazal skupni rezultat vprašalnika o kakovosti življenja bolnikov z rinitisom in konjunktivitisom.
Azoospermia (no sperm count)
azoospermija (odsotnost semenčic),
Azoospermia Amenorrhoea Vaginal haemorrhage
azoospermija amenoreja vaginalna krvavitev
AZOPT 10 mg/ml eye drops, suspension Brinzolamide
AZOPT 10 mg/ml kapljice za oko, suspenzija brinzolamid
AZOPT contains a preservative (benzalkonium chloride) which may cause eye irritation and is known to discolour soft contact lenses.
Zdravilo AZOPT vsebuje konzervans (benzalkonijev klorid), ki lahko povzroči draženje očesa in znano je, da spremeni barvo mehkih kontaktnih leč.
AZOPT has a minor influence on the ability to drive and use machines.
Zdravilo AZOPT ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
AZOPT has not been studied in patients with hepatic impairment and is therefore not recommended in such patients.
Zdravila AZOPT še niso preskušali pri bolnikih z jetrno okvaro in ga pri njih zato ne priporočamo.
AZOPT has not been studied in patients with narrow-angle glaucoma and its use is not recommended in these patients.
Zdravila AZOPT še niso preskušali pri bolnikih z glavkomom ozkega zakotja, zato njegova uporaba pri teh bolnikih ni priporočljiva.
AZOPT is a milky liquid (a suspension) supplied in a pack containing a 5 ml or a 10 ml plastic (droptainer) bottle with a screw cap, or in a pack containing three 5 ml plastic (droptainer) bottles with screw caps.
AZOPT je mlečnobela tekočina (suspenzija), ki je na voljo v pakiranjih s 5 ml ali 10 ml kapalnim vsebnikom (droptainer) z navojno zaporko ali v pakiranjih s tremi 5 ml kapalnimi vsebniki (droptainer) z navojno zaporko.
AZOPT may cause the same allergy. if you have too much acidity in your blood (a condition called hyperchloraemic acidosis).
Zdravilo AZOPT lahko povzroči enako vrsto alergije. če imate preveliko kislost krvi (motnja, ki jo imenujemo hiperkloremična acidoza).
Azotaemia (uraemia)
azotaemija (uremija)
Azotaemia, chromaturia
azotemija, kromaturija
Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including
Aztreonam kaže in vitro aktivnost proti gram-negativnim aerobnim povzročiteljem bolezni, vključno s
b 1.2 ml = maximum delivered volume per vial (Xolair 150 mg).
b 1,2 ml = največji injicirani volumen na vialo (Xolair 150 mg).
b 388 patients assessed in gemcitabine-treated group c 404 patients assessed in Abraxane/gemcitabine-treated group
b 388 bolnikov ocenjenih v skupini, zdravljeni z gemcitabinom c 404 bolniki ocenjeni v skupini, zdravljeni z zdravilom Abraxane in gemcitabinom
b 48 weeks of double-blind tenofovir disoproxil fumarate followed by 48 weeks open-label.
b 48-tedensko dvojno slepo zdravljenje z dizoproksiltenofovirijevim fumaratom, ki mu sledi 48-tedensko odprto zdravljenje.
b 95% confidence interval about the median overall survival time. c Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups. d The p-value is based on an unstratified log-rank test.
b 95 % interval zaupanja glede mediane časa celokupnega preživetja. c Na podlagi modela sorazmernih ogroženosti po Coxu s primerjavo funkcij tveganja, povezanih z zdravljenimi skupinami. d Vrednost p temelji na nestratificiranem testu log-rank.
b 95% confidence interval about the median progression free survival time. c Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age (≤75 vs >75),diseases population (refractory to both Lenalidomide and Bortezomib vs not refractory to both drugs), and prior number of anti myeloma therapy (=2 vs >2). d The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model.
b 95 % interval zaupanja pri mediani časa preživetja brez napredovanja. c Na podlagi modela sorazmernih ogroženosti po Coxu s primerjavo funkcij tveganja, povezanih z zdravljenimi skupinami, stratificiranimi po starosti (≤ 75 v primerjavi z > 75), bolezni prebivalstva (neodzivni na lenalidomid in bortezomib v primerjavi z odzivnimi na obe zdravili) in predhodnim številom terapij proti plazmocitomu (= 2 v primerjavi z > 2). d Vrednost p temelji na stratificiranem testu log-rank z enakimi stratifikacijskimi faktorji kot zgornji Coxov model.
b a primary endpoint c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)
b primarni opazovani dogodek c Roche Cobas Amplicor PCR test (LLOQ = 300 kopij/ml)
b a primary endpoint. c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)
b primarni opazovani dogodek. c Roche Cobas Amplicor PCR test (LLOQ = 300 kopij/ml)
b ATV/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily). c LPV/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily). d Confidence interval.
b ATV/RTV skupaj s tenofovirjem/emtricitabinom (fiksni odmerek 300 mg/200 mg tablete enkrat na dan). c LPV/RTV skupaj s tenofovirjem/emtricitabinom (fiksni odmerek 300 mg/200 mg tablete enkrat na dan). d Interval zaupanja.
B cell counts returned to normal in these animals within 6 months of birth and did not compromise the reaction to immunization.
Število celic B se je pri teh živalih vrnilo na normalno raven v 6 mesecih po rojstvu in ni ogrožalo reakcije na imunizacijo.
B cell counts returned to normal levels in the offspring, and immunologic function was restored within 6 months of birth.
Število celic B se je pri potomstvu normaliziralo in imunološko delovanje obnovilo v 6 mesecih po rojstvu.
B cell levels in human neonates following maternal exposure to MabThera have not been studied in clinical trials.
V kliničnih preskušanjih niso proučevali števila celic B pri novorojenčkih mater, zdravljenih z zdravilom MabThera.
b Disease Control Rate = SD+ ORR
b Stopnja nadzora bolezni = SD+ ORR
b e.g. increased tendency to bruise, spontaneous haematoma, haemorrhagic diathesis c Identified in post-marketing experience d Frequencies derived from lab observations (Uric acid increases to >upper limit of normal from baseline below or within reference range.
bnpr. večja nagnjenost k podplutbam, spontanim hematomom, hemoragični diatezi c Ugotovljeni med uporabo po prihodu zdravila na trg d Pogostnosti na podlagi laboratorijskih opažanj (Zvišanje sečne kisline na > zgornjo normalno mejo od izhodiščne vrednosti pod referenčnim območjem ali znotraj njega.
B Frequencies of all uncommon adverse reactions were based on the individual mono-components data.
B Pogostnosti vseh občasnih neželenih učinkov so temeljile na podatkih o posameznih učinkovinah.
b Frequency is based on laboratory values.
b Pogostnost temelji na laboratorijskih vrednostih.
b Includes (very common) stomatitis, mouth ulceration, aphthous stomatitis and (uncommon) gingival pain, glossitis, lip ulceration, tongue ulceration c Includes (common) rash, rash erythematous, erythema and (uncommon) rash macular, rash maculo-papular, rash generalised d Frequency based upon number of women from 10 to 55 years of age while on treatment in the pooled data
b Vključuje stomatitis in razjede v ustih in aftozni stomatitis (zelo pogosti) ter boleče dlesni, vnetje jezika, razjede na ustnicah in razjede na jeziku (občasni). c Vključuje izpuščaj, eritematozni izpuščaj in eritem (pogosti) ter makularni izpuščaj, makulopapularni izpuščaj in generalizirani izpuščaj (občasni). d Pogostnost temelji na številu žensk, ki so bile v času zdravljenja stare od 10 do 55 let, iz združene baze podatkov.
B Infusion solution concentration is 0.77 mg/mL
B Koncentracija infuzijske raztopine je 0,77 mg/ml.
B Infusion solution concentration is 0.77 mg/mL
BKoncentracija infuzijske raztopine je 0,77 mg/ml.
b L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology c adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al)
bL1 protein v obliki virusu podobnih delcev, pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces cerevisiae CANADE 3C-5 (sev 1895)) cadsorbiran na amorfni aluminijev hidroksifosfat sulfat kot adjuvans (225 mikrogramov Al)
b low-titer transient inhibitor formation
b tvorba nizkih titrov prehodnih inhibitorjev
B LS mean and CI based on an ANCOVA model with baseline BCVA measurement as a covariate and a factor for treatment group.
B) Povprečje najmanjših kvadratov (LS) in interval zaupanja (IZ) temeljita na podlagi modela ANCOVA z izhodiščnimi vrednostmi BCVA kot kovariance in dejavnikom za skupino zdravljenja.
b n = 292 c Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects).
b n = 292 c Analiza se nanaša na preiskovance, ki so imeli psoriazo nohtov na začetku študije (81,8 % preiskovancev).
b n = 292. c Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects).
b n = 292 c Analiza se nanaša na preiskovance, ki so imeli psoriazo nohtov na začetku študije (81,8 % preiskovancev).
b n includes all patients who received at least one day of apheresis
b n zajema vse bolnike, pri katerih se je izvajala afereza najmanj en dan.
B n=132 a
B n=132a
B n=200 a
B n=200a
b p < 0.001 compared with etanercept
b p < 0,001 v primerjavi z etanerceptom
b p < 0.05 c nominally significant (p < 0.05)
b p < 0,05 p = NS
b p < 0.05. c Not applicable. d p < 0.001.
b p < 0,05 c N/A: navedba ni smiselna d p < 0,001
b p < 0.05. c Not applicable. d p < 0.001.
b p < 0,05. c N/A: navedba ni smiselna d p < 0,001.
b p-value=0.015
b vrednost p = 0,015
b p<0.001.
kovariablami. b p<0.001.
b p0.001 compared with placebo c A significant reduction in the incidence of hip fractures has not been demonstrated d p0.025 compared with placebo.
bp  0,001 v primerjavi s placebom cPomembnega zmanjšanja incidence zlomov kolka niso dokazali. dp  0,025 v primerjavi s placebom
b Reported in  2 patients receiving KANUMA
b O njih so poročali pri  2 bolnikih, ki sta dobivala zdravilo KANUMA
b REYATAZ/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
b Zdravilo REYATAZ/RTV skupaj z dizoproksiltenofovirat fumaratom/emtricitabinom (fiksni odmerek 300 mg/200 mg tablete enkrat na dan).
b REYATAZ/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
b Zdravilo REYATAZ/RTV skupaj s tenofovirjem/emtricitabinom (fiksni odmerek 300 mg/200 mg tablete enkrat na dan).
b Subgroup analysis for patients on additional background of metformin (PPS-Completers, LOCF)
b Analiza pri podskupinah bolnikov ob dodatni prisotnosti metformina (bolniki, ki so zaključili zdravljenje v populaciji po protokolu (PPS, per protocol (population) set, zadnje opazovanje preneseno naprej (LOCF, Last Observation Carried Forward))
B Symptoms
Stadij po Raiju III/IV
b Tabulated summary of adverse events
Povzetek neželenih učinkov, prikazan v preglednici
B Turn the dose selector until the dose pointer lines up with your dose.
Zavrtite izbirnik odmerka, dokler kazalnik odmerka ni uravnan z vašim odmerkom.
b Visually inspect the reconstituted solution for particulate matter or discoloration during reconstitution and prior to infusion.
Med pripravo in pred infundiranjem pripravljeno raztopino preglejte in se prepričajte, da ni obarvana in ne vsebuje delcev.
b Visually inspect the reconstituted solution for particulate matter or discolouration during reconstitution and prior to infusion.
Med pripravo in pred infundiranjem pripravljeno raztopino preglejte in se prepričajte, da ni obarvana in ne vsebuje delcev.
B) BCVA: Best Corrected Visual Acuity
B) BCVA: najboljša korigirana ostrina vida (Best Corrected Visual Acuity)
b) By continuous infusion
b) s kontinuirano infuzijo